

# PATENT COOPERATION TREATY

From the  
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

VIEILLEFOSSE J-CLAUDE  
HOECHST MARION ROUSSEL  
102, route de Noisy  
F-93235 Romainville Cedex  
FRANCE

## PCT

### NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Rule 71.1)

Date of mailing (day/month/year)	22.12.2000
-------------------------------------	------------

Applicant's or agent's file reference JH98K011/PCT	<b>IMPORTANT NOTIFICATION</b>
---	-------------------------------

International application No. PCT/IB99/01621	International filing date (day/month/year) 04/10/1999	Priority date (day/month/year) 09/10/1998
---	--	--

Applicant HOECHST MARION ROUSSEL et al.
--

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/	Authorized officer
---------------------------------------	--------------------



European Patent Office  
D-80298 Munich  
Tel. +49 89 2399 - 0 Tx: 523656 epmu d  
Fax: +49 89 2399 - 4465

Papiol Rovira, M

Tel. +49 89 2399-7199



## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C. 20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 16 May 2000 (16.05.00)	
<b>International application No.</b> PCT/IB99/01621	<b>Applicant's or agent's file reference</b> JH98K011/PCT
<b>International filing date</b> (day/month/year) 04 October 1999 (04.10.99)	<b>Priority date</b> (day/month/year) 09 October 1998 (09.10.98)
<b>Applicant</b> KATSUURA, Mieko et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

01 April 2000 (01.04.00)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Olivia RANAIVOJAONA


Telephone No.: (41-22) 338.83.38

# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference JH98K011/PCT		FOR FURTHER ACTION		See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/IB99/01621	International filing date (day/month/year) 04/10/1999	Priority date (day/month/year) 09/10/1998		
International Patent Classification (IPC) or national classification and IPC C07K14/51				
Applicant HOECHST MARION ROUSSEL et al.				
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 4 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>				
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> <li>I <input checked="" type="checkbox"/> Basis of the report</li> <li>II <input type="checkbox"/> Priority</li> <li>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</li> <li>IV <input type="checkbox"/> Lack of unity of invention</li> <li>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</li> <li>VI <input type="checkbox"/> Certain documents cited</li> <li>VII <input type="checkbox"/> Certain defects in the international application</li> <li>VIII <input checked="" type="checkbox"/> Certain observations on the international application</li> </ul>				
Date of submission of the demand 01/04/2000		Date of completion of this report 22.12.2000		
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized officer  Halle, F  Telephone No. +49 89 2399 8537		



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/IB99/01621

**I. Basis of the report**

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:

**Description, pages:**

1-23 as originally filed

**Claims, No.:**

1-13 as originally filed

**Drawings, sheets:**

1/2-2/2 as originally filed

**Sequence listing part of the description, pages:**

1-9, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/IB99/01621

- ☐ the description,      pages:  
☐ the claims,      Nos.:  
☐ the drawings,      sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes: Claims 1-13
	No: Claims
Inventive step (IS)	Yes: Claims 1-13
	No: Claims
Industrial applicability (IA)	Yes: Claims 1-13
	No: Claims

- 2. Citations and explanations**  
**see separate sheet**

**VIII. Certain observations on the international application**

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/IB99/01621

**Point I**

The application comprises sequence listing sheets 1-9.

**Point V**

Having regard to the prior art, the subject-matter of claims 1-13 appears to be novel and to involve an inventive step. The invention relates to proteins having antagonistic activity against bone morphogenetic proteins (BMP).

The document EP-A-0 691 349, which is considered to represent the most relevant state of the art, discloses analogs of BMPs; see for example claim 1 of said document. The subject-matter of the present independent claims 1, 9, 10, 12 and 13 differs from the disclosure of said document in that the presently claimed antagonistic proteins do not have a linker within the protein structure. As a result, the general structure of the presently claimed protein having antagonistic activity against BMP is fundamentally different from the general structure of the prior art BMP analogs. Furthermore, having regard to the above cited prior art, the structure of the presently claimed protein wherein certain amino acid residues as e.g. methionine have been converted to hydrophilic residues does not appear to be obvious to the skilled person.

**Point VIII**

The terms "at least one residue..." used in independent claims 1, 9 and 10 are vague and indefinite and leave the reader in doubt as to the meaning of the technical features to which they refer, thereby rendering the definition of the subject-matter of said claims unclear (Article 6 PCT).

A similar remark applies to independent claims 12 and 13 directed to an "agent for therapy" which contains the protein of claims 1, 9 and 10 objected to above.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 14/51, A61K 38/18, A61P 19/00, 21/00, 9/10</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/21998</b> <b>(43) International Publication Date:</b> 20 April 2000 (20.04.00)
<b>(21) International Application Number:</b> PCT/IB99/01621 <b>(22) International Filing Date:</b> 4 October 1999 (04.10.99)  <b>(30) Priority Data:</b> 10/288103 9 October 1998 (09.10.98) JP  <b>(71) Applicant (for all designated States except US):</b> HOECHST MARION ROUSSEL [FR/FR]; 1, terrasse Bellini, F-92800 Puteaux (FR).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> KATSUURA, Mieko [JP/JP]; 2-14-2-106, Sakae-cho, Higashimurayama-shi, Tokyo 189-0013 (JP). KIMURA, Michio [JP/JP]; 9-8-304, Tsurugadai, Chigasaki-shi, Kanagawa 253-0003 (JP).  <b>(74) Agent:</b> VIEILLEFOSSE, Jean, Claude; Hoechst Marion Roussel, 102, route de Noisy, F-93235 Romainville Cedex (FR).		<b>(81) Designated States:</b> AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> BONE MORPHOGENETIC PROTEIN ANTAGONIST BASED ON THE MATURE PROTEIN  <b>(57) Abstract</b>  The purpose is to provide a mature protein having an antagonistic activity against bone morphogenetic proteins. The mature protein having an antagonistic activity against bone morphogenetic proteins is obtained by converting at least one residue among methionine residues or tryptophane residues existing in the amino acid sequence of mature human MP52 (SEQ ID N° 1) to a hydrophilic residue by chemical modification, or replacing said residues with a hydrophilic amino acid residue or a polar amino acid residue. The chemical modification for said methionine residue is performed by an oxidization reaction or an alkylation reaction. The chemical modification for said tryptophane residue is performed by an allylsulphenylation reaction. Or a mature protein having an antagonistic activity against bone morphogenetic proteins is obtained by converting at least one residue of tryptophane residues existing in the amino acid sequences of mature human BMP-2 (SEQ ID N° 2), mature human BMP-4 (SEQ ID N° 3), and mature human BMP-7 (SEQ ID N° 4) to a hydrophilic residue by chemical modification, or replacing said residues with a hydrophilic amino acid residue or a polar amino acid residue.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						



## MATURE PROTEIN HAVING ANTAGONISTIC ACTIVITY AGAINST BONE MORPHOGENETIC PROTEIN

### BACKGROUND OF THE INVENTION

#### 5 (1) Field of the Invention

This invention relates to a mature bone morphogenetic protein of which some hydrophobic amino acid residues are exchanged to a hydrophilic or a polar amino acid residue by chemical modification or genetic engineering technology. The mature proteins of this invention show an antagonistic activity against bone morphogenetic proteins, and are useful for medicinal agents to suppress symptoms of ectopic osteogenesis and ectopic calcification or metabolic bone diseases with calcification such as neurotic osteosis, ectopic ossification caused by stress of operation, traumatic myositis ossificans, ossification by defect of oxygen supply, osteogenic tumor, ossification of the posterior longitudinal ligament, and arterial sclerosis.

#### (2) Description of the Related Art

20 A bone morphogenetic protein (hereinafter called BMP) is a protein having a bone morphogenetic activity in decalcified bone tissue. Although the isolation of BMP had been worked on energetically since the 1970s, it was quite difficult to isolate as a single protein. Gene cloning of BMP as expected was performed by Wozney in 1989 by molecular biological technology, using the amino acid sequences derived from unknown peptides which were separated by treating the fraction having bone morphogenetic activities with an enzyme. The gene was immediately introduced to the animal cultured cells, and the activity of the protein expressed was measured in vivo, and BMP activity in the protein was practically proved (Wang, E. A. et al., (1990) Proc. Natl. Acad. Sci. USA, vol. 87, p. 2220-2224). Continuing cloning a protein with bone morphogenetic activities utilizing homology, several numbers of the proteins with bone morphogenetic activities in a similar structure have been isolated so far. Those proteins all belong to TGF (transforming growth factor)- $\beta$  superfamily and are proved to have the activity to

cause ectopic ossification *in vivo*, basically. Ossification caused by BMP is said to be internal cartilaginous and it seems to reproduce the formation of long bone at an embryonal stage. Therefore, BMP itself can be used as a medicinal agent for the treatment to compensate the bone deficit.

On the other hand, since BMP genes were disclosed and the specific antibodies against BMPs were prepared, BMPs were also expressed at the site of ectopic calcification, which have not had any medical treatment so far, and there seem some possibilities of the relationship between BMPs and those diseases. For example, it becomes recently evident that BMP exists or is included in diseases such as neurotic osteosis, ectopic ossification caused by stress of operation, traumatic myositis ossificans, ossification by defect of oxygen supply, osteogenic tumor, specified as refractory diseases such as ossification of the posterior longitudinal ligament (OPLL) (Spine, 17-3S, S33, 1992) and calcification part of arterial sclerosis (J. Clin. Invest., vol. 91, p. 1800, 1993). In addition, the major symptoms of pseudomalignant heterotopic ossification (PHO), pseudomalignant osseous tumor and myositis ossificans circumscripta are ache and the appearance of the hard tissue mass in the muscle. Though the causes of these diseases are still unknown in detail, BMP seems to have a relationship with the appearance of hard tissue in the muscle of the patients. It is considered that BMP exists in the tissue in which BMP does not exist naturally, acts on autocrine, and forms bone like hard tissue. There is no effective treatment for OPLL by now. When the compressive neural symptom is critical, an excision is operated. However the prognosis is not so good. There is no treatment for calcification of artery, neither.

It seems that suppression of BMP existence may be one of the major treatments for these diseases. Another treatment, such as administration of BMP antagonists, also seems effective. BMP receptors, neutralized antibodies against BMP and the BMP peptides corresponding to the binding site, a BMP with chemically modified specific amino acid residue are thought to have BMP antagonist-like activity.

Many studies have been so far carried out concerning a relationship between the structure and the activity of BMPs and it is speculated that some sites of mature BMPs relate to the receptor binding. It is known that a peptide synthesized based on these studies works as an antagonist against BMPs (JP patent application, Hei 7 ('95)- 200175).

#### SUMMARY OF THE INVENTION

Other than the synthetic peptides, many kinds of methods are desired to exist for therapy of various diseases of bones and cartilages such as hyperplasia. The purpose of this invention is to provide a new BMP antagonist protein as an effective therapeutic agent for above bone-related diseases in which a specific amino acid residue is chemically modified or replaced by genetic engineering technology.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 shows a comparison of ALPase inducing activities by methionine alkylated mature human MP52s and that of unmodified mature human MP52 in MC3T3-E1 cells, which were separated by the difference in the retention time on the reverse phase HPLC. In the figure, the solid line with solid circles represents unmodified mature human MP52, the solid line with solid squares represents one-methionine alkylated mature human MP52, the broken line with solid triangles represents two-methionine alkylated mature human MP52, the solid line with open circles represents three-methionine alkylated mature human MP52, the dotted line with open triangles represents four-methionine alkylated mature human MP52, respectively. The solid circles shown in of the Y-axis represents ALPase activity in cells without treated by any reagent.

Fig. 2 shows the antagonistic activity of methionine oxidized mature human MP52 and tryptophane allylsulphenylated mature human MP52 in different cell lines. (A) represents their antagonistic activities against mature rh-BMP-2 in C3H10T  $\frac{1}{2}$  cells and (B) shows their antagonistic activities against mature human MP52 in MC3T3-E1 cells, respectively. In both figures, the solid line with solid circles represents tryptophane allylsulphenylated mature human MP52 and the

dotted line with open circles represents methionine oxidized mature human MP52, respectively. In (A), the solid square shows ALPase activity induced by 300 ng/ml of mature rh-BMP-2 alone in C3H10T  $\frac{1}{2}$  cell. In (B) the solid square shows ALPase activity induced by 600 ng/ml of unmodified mature human MP52 alone in MC3T3-E1 cells. Open squares represent the activity in the experiments without any reagent.

#### DESCRIPTION OF THE PREFERRED EMBODIMENT

10 The present invention relates to a mature protein having an antagonistic activity against bone morphogenetic proteins, obtained by converting at least one residue among methionine residues or tryptophane residues existing in the amino acid sequence of mature human MP52 (SEQ ID N° 1) to a hydrophilic residue by chemical modification, or replacing said residues  
15 with a hydrophilic amino acid residue or a polar amino acid residue by genetic engineering technology.

When at least one residue of said methionine is converted, chemical modification for said methionine residue  
20 is an oxidization reaction or an alkylation reaction.

When the chemical modification of said methionine residue is an oxidization reaction, among the preferred mature proteins of the invention is that in which four methionine residues are oxidized and having the amino acid  
25 sequence of SEQ ID N° 5.

When the chemical modification of said methionine residue is an alkylation reaction, among the preferred mature proteins of the invention is that in which at least one methionine residue is S-carboxymethylated and having the  
30 amino acid sequence of SEQ ID N° 6.

When at least one residue of said tryptophane is converted, chemical modification for said tryptophane residue is an allylsulphenylation reaction.

Among the preferred mature proteins of the invention is  
35 that in which two tryptophane residues are allylsulphenylated and having the amino acid sequence of SEQ ID N° 7.

The present invention relates to mature proteins of the invention as defined above having an antagonist activity

against bone morphogenetic proteins wherein said mature human MP52 is a dimer protein.

Further, the present invention relates to a mature protein having an antagonistic activity against bone morphogenetic proteins, obtained by converting at least one residue of tryptophane residues existing in the amino acid sequence of mature human BMP-2 (SEQ ID N° 2), mature human BMP-4 (SEQ ID N° 3), or mature human BMP-7 (SEQ ID N° 4) to a hydrophilic residue by chemical modification, or replacing said residues with a hydrophilic amino acid residue or a polar amino acid residue by genetic engineering technology.

Furthermore, the present invention relates to a mature protein having an antagonistic activity against bone morphogenetic proteins, obtained by replacing at least one amino acid residue of three hydrophobic amino acid residues, among said hydrophobic amino acid residues relating to a receptor binding site in the amino acid sequence of mature human BMP-2 (SEQ ID N° 2), mature human BMP-4 (SEQ ID N° 3), or mature human BMP-7 (SEQ ID N° 4), which are located in positions corresponding to those of methionine residues located in 30th, 71st, and 74th positions of the amino acid sequence of mature human MP52 (SEQ ID N° 1), with a hydrophilic amino acid residue or a polar amino acid residue by genetic engineering technology.

The present invention relates to mature proteins of the invention as defined above having an antagonist activity against bone morphogenetic proteins, wherein said mature human BMP-2, mature human BMP-4 or mature human BMP-7 is a dimer protein.

The present invention, further, relates to an agent for therapy and/or prevention of ectopic ossification, containing a mature protein of the invention defined above as an effective ingredient showing an antagonistic activity against bone morphogenetic proteins.

Furthermore, the present invention relates to an agent for therapy and/or prevention of metabolic diseases with calcification, containing a mature protein of the invention defined above as an effective ingredient showing an

antagonistic activity against bone morphogenetic proteins.

The proteins belonging to the TGF- $\beta$  superfamily are each presumed from its gene structure to be synthesized as a precursor in cells and to be formed into a mature (active type) peptide homodimer after various processings. The active type of mature human TGF- $\beta$ 1 is known to be a dimer of the peptide of COOH-terminal 112 residues (Nature, 316, 701-705, 1985). The term "mature BMP" as used herein means a BMP which is substantially composed of an amino acid sequence homologous with COOH-terminal 112 amino acid residues of active type of human TGF- $\beta$ 1. The proteins belonging to the TGF- $\beta$  superfamily in the present invention are exemplified as BMP-2, BMP-4, BMP-7, human MP52 and so on.

The inventors attempted a chemical modification and a replacement with an amino acid for human MP52 that belongs to TGF- $\beta$  superfamily and particularly that is a member of BMP family, with a purpose of preparing a chemically modified protein strongly acting as a BMP antagonist through binding to BMP binding site on the receptor.

It is assumed that the activated type of human MP52 is a dimer form and that the receptor binding site of mature MP52 is an exposed part on the outside of the protein molecule. Thus, the receptor binding site is speculated that it is composed of two vicinal peptide regions (the amino acid positions from the 20th Arg to the 38th Ala and from 60th Glu to 77th Glu in SEQ ID N° 1 of the Sequence Listing) in formation of a dimer of human MP52.

We prepared a protein of which two kinds of amino acid residues were chemically modified because it is known that the content of tryptophane and methionine is generally low in amino acid composition of the protein allowing selective chemical modification, and from the assumed three-dimensional structure of human MP52 that three (30th, 71st, and 74th positions) of four methionine residues in the monomer of mature human MP52 exist in the assumed receptor binding site and that both (32nd and 35th) of two tryptophane residues in the monomer of mature human MP52 exist in the assumed receptor binding site of mature MP52.

Chemical modification of this invention means that the side chains of methionine or tryptophane are modified in a degree enough to make the protein inactive with keeping a binding ability to the receptor. For the chemical  
5 modification, a conventional method in studies on protein chemistry is applied. The method is described in "Protein Chemistry IV," pp 6-118, 1977, Jap. Soc. Biochem. Methionine is a hydrophobic amino acid and can be modified into a hydrophilic residue by chemical modification. Chemical  
10 modifications in increasing hydrophilicity are exemplified by oxidization of methionine to make methionine sulfoxide or methionine sulfon using an oxidant and by alkylation to make S-carboxymethylmethionine using  $\alpha$ -halogenoacetic acid. The oxidization of methionine are performed by hydrogen peroxide,  
15 performic acid, periodic acid, N-chlorosuccinimide, and N-bromosuccinimide. Besides, for  $\alpha$ -halogenoacetic acid, monoiodoacetic acid and monoiodoacetamide can be used.

Chemical modification to indole ring of tryptophane gives a subtle change of environment and structure nearby it.  
20 Suitable examples are allylsulphenylation of the second position of indole nucleus by p- or o-nitrophenylsulphenylchloride, 2-nitro-4-carboxyphenylsulphenylchloride, 2,4-dinitrophenylsulphenylchloride, or 2-hydroxy-5-nitrobenzylation of the 3rd position of indole nucleus by 2-  
25 hydroxy-5-nitrobenzylbromide, dimethyl(2-hydroxy-5-nitrobenzyl)sulfonylbromide.

The present invention in particular relates to a mature protein of which one to 4 methionine residues or 1 to 2 tryptophane residues are chemically modified in mature human  
30 MP52 amino acid sequence shown in SEQ ID N° 1 of the Sequence Listing.

The protein shown in SEQ ID N° 1 of the Sequence Listing can be produced by the method described in International Patent Application WO 96/33215. Since 3 out of 4 methionine  
35 residues exist in the receptor binding site of mature human MP52 produced by said method, and all 2 tryptophane residues exist there, and whose amino acids are all hydrophobic, it is assumed that these hydrophobic amino acids play an important

role in bone morphogenetic activity.

Mature human MP52 of the present invention includes not only the mature protein with the amino acid sequence shown in SEQ ID N° 1 of the Sequence Listing but also Ala or Arg-Ala  
5 binding to the N-terminus of the amino acid sequence of said mature protein as disclosed respectively in international patent application WO 95/04819 and WO 97/06254.

Comparing the amino acid sequences of the mature proteins of other BMPs such as human BMP-2 (SEQ ID N° 2),  
10 human BMP-4 (SEQ ID N° 3), human BMP-7 (SEQ ID N° 4) and so on with that of mature human MP52 protein, it is found that in those bone morphogenetic proteins the amino acids corresponding to the positions of methionine residues of mature human MP52 are all methionine residues or hydrophobic  
15 amino acids.

In concrete, the receptor binding site of mature human BMP-2 is estimated to be the peptides with the amino acid sequence from 16th Arg to 34th Ala and from 56th Asn to 73th Lys shown in SEQ ID N° 2 of the Sequence Listing (Science  
20 242, 1528-1534, 1988). The amino acids of mature human BMP-2, which corresponds to methionines' position of the mature human MP52 (30th, 71st and 74th), are replaced with 26th Val, 67th Val and 70th Val.

The receptor binding site of mature human BMP-4 is  
25 estimated to be the peptides with the amino acid sequence from 18th Arg to 36th Ala and from 58th Asn to 75th Ser shown in SEQ ID N° 3 of the Sequence Listing (DNA Seq. 5 (5), 272-275, 1995). The amino acids of mature human BMP-4, which corresponds to methionines' position of mature human MP52  
30 (30th, 71st and 74th), are replaced with 28th Val, 69th Val and 72rd Val.

The receptor binding site of mature human BMP-7 is estimated to be the peptides with the amino acid sequence from 40th Lys to 58th Ala and from 80th Asn to 97th Glu shown  
35 in SEQ ID N° 4 of the Sequence Listing (Proc. Natl. Acad. Sci. U.S.A. 93(2), 878-883, 1996). The amino acids of mature human BMP-7, which corresponds to methionines' position of mature human MP52 (30th, 71st and 74th), are replaced with



50th Leu, 91st Val and 94th Ile.

It is difficult to carry out a chemical modification selectively on the hydrophobic amino acids of which positions correspond to those of methionine of mature human MP52.

5 However, it is possible to replace hydrophobic amino acids with hydrophilic or polar amino acids by genetic engineering technology.

Since the tryptophane residues are conserved in all BMPs described above, it is possible to replace hydrophobic amino  
10 acids with hydrophilic or polar amino acids by chemical modification method or genetic engineering technology. The tryptophane residues also play an important role in making a change in a three-dimensional structure in chemical modification and genetic engineering technology.

15 Thus, the present invention relates to mature human MP52, in particular, which is obtained by converting one to 4 methionine residues or one to 2 tryptophane residues existing in the amino acid sequence shown in SEQ ID N° 1 of the Sequence Listing to hydrophilic residues or polar amino acid  
20 residues by recombinant engineering technology. In the present invention hydrophilic amino acids and polar amino acids are aspartic acid, glutamic acid, lysine, arginine, histidine, serine, threonine and so on. In the present invention, when methionine residues or tryptophane residues  
25 are converted to other hydrophilic or polar amino acids, the protein of the present invention can be obtained by transforming a recombinant DNA into *E. coli* which are made by replacing the codons corresponding to methionines at 30th, 71st, 74th and 111th positions or the codons corresponding to  
30 tryptophanes at 32nd and 35th positions shown in SEQ ID N° 1 replaced with the codons of aspartic acid, glutamic acid, lysine, arginine, histidine, serine, threonine and so on or by making.

Further, the present invention relates to any mature  
35 proteins having the amino acid sequence shown in SEQ ID Nos 2 to 4, of which one to two tryptophane residues are subjected to chemical modification.

The present invention furthermore relates to any mature

proteins having the amino acid sequence shown in SEQ ID Nos 2 to 4, in which hydrophobic amino acids consisting of the receptor binding site, 1 to 3 hydrophobic amino acids corresponding to the positions of 30th, 71st and 74th methionine residues or 1 to 2 tryptophane residues are replaced with hydrophilic amino acids or polar amino acids. In the present invention, hydrophobic amino acids are methionine, valine, leucine, isoleucine or tryptophane.

The present invention relates to the mature protein having the amino acid sequence shown in SEQ ID N° 5 of the Sequence Listing, in which 4 methionine residues of the methionine residues are oxidized. In detail, for the oxidization of methionine residue, hydrogen peroxide is added at a final concentration of 0.014% to 2 mg/ml of the mature protein and the reaction is carried out for more than 15 hours at room temperature and then the mature protein of which methionine residues are in methionine sulfoxide can be obtained.

The present invention relates to the mature protein having the amino acid sequence shown in SEQ ID N° 6 of the Sequence Listing, in which 1 to 4 methionine residues of the methionine residues are alkylated. In detail, monoiodoacetic acid is added at a concentration of higher than methionine residues by 50 to 100 at the molar ratio to 2 mg/ml of the mature protein and the reaction is carried out for more than 15 hours at room temperature and then the mature protein of which methionine residues are S-carboxymethylated can be obtained.

The present invention relates to the mature protein having the amino acid sequence shown in SEQ ID N° 7 of the Sequence Listing, in which 2 tryptophane residues of the tryptophane residues are allylsulphenylated. In detail, 20 equivalents of p-nitrophenylsulphenyl chloride in 100% acetic acid is added to 2 mg/ml of the mature protein and the reaction is carried out for 1 hour at room temperature and then the mature protein of which tryptophane residues are allylsulphenylated can be obtained.

The present invention relates to the mature protein

having an amino acid sequence shown in SEQ ID N° 2 of the Sequence Listing, in which 1 to 2 tryptophane residues at 28th and 31st are allylsulphenylated.

5 The present invention relates to the mature protein having an amino acid sequence shown in SEQ ID N° 2 of the Sequence Listing, in which one or all of 26th, 67th and 70th valine residues or one or both of 28th and 31st tryptophane residues are replaced with aspartic acid, glutamic acid, lysine, arginine, histidine, serine, threonine and so on.

10 The present invention relates to the mature protein having an amino acid sequence shown in SEQ ID N° 3 of the Sequence Listing, in which one or both of 30st and 33th tryptophane residues are allylsulphenylated.

15 The present invention relates to the mature protein having an amino acid sequence shown in SEQ ID N° 3 of the Sequence Listing, in which one or all of 28th, 69th and 72rd valine residues or one or both of 30st and 33th tryptophane residues are replaced with aspartic acid, glutamic acid, lysine, arginine, histidine, serine, threonine and so on.

20 The present invention relates to the mature protein having an amino acid sequence shown in SEQ ID N° 4 of the Sequence Listing, in which one or both of 52nd and 55th tryptophane residues are allylsulphenylated.

25 The present invention relates to the mature protein having an amino acid sequence shown in SEQ ID N° 4 of the Sequence Listing, in which one or all of 50th leucine, 91st valine, 94th isoleucine, 131th methionine or one or both of 52nd and 55th tryptophane residues are replaced with aspartic acid, glutamic acid, lysine, arginine, histidine, serine, 30 threonine and so on.

The BMP antagonist-like activity of the protein modified chemically or replaced with other amino acids in the present invention can be proved by measuring alkaline phosphatase (ALPase) activity as a marker of biological activity by 35 adding in a culture medium of a murine carvarial clonal cell line (MC3T3-E1 cell) having osteoblastic property which Kodama et al. established (Kodama, H. et al. (1981) Jpn. J. Oral Biol., vol. 23, p.899). ALPase is often used as a

marker enzyme for differentiation/maturation in osteoblasts and cartilage cells (Pfeilschifter, J., et al., Endocrinology (1987), vol. 121, p 212-218; Rodan, G. A., et al., Calcium regulating hormones and bone metabolism, Elsevier Science Publishers B.V., (1992), p 183-196).

5 The mature protein obtained by examples 1 to 3 in the present invention inhibited dose-dependently the increase of ALPase activities which were induced by recombinant mature human BMP-2 (rh-BMP-2) or mature human MP52 in MC3T3-E1 cell line and C3H10T  $\frac{1}{2}$  cell line having osteoblastic property.

10 The result indicated that the protein in the present invention could inhibit not only the activity of human MP52 but also the activities of other BMPs.

15 The present invention relates to an agent for therapy and/or prevention of ectopic ossification, containing any protein described above as an effective ingredient.

20 Furthermore, the present invention relates to an agent for therapy and/or prevention of metabolic diseases with calcification, containing any mature protein described above as an effective ingredient.

25 The protein of the present invention is effective in therapy as an agent of suppressing worsening condition of OPLL and arterial sclerosis, treating tumor in bone and cartilage in which BMP is expressed and treating other metabolic bone diseases. It can suppress worsening condition by lowering the function of osteoblasts by using over cycle of metabolic bone such as Paget's disease. It can also be useful as a reagent for screening or evaluating systems of medicinal agents which compete with BMP and the receptor binding.

30 The administrating method can be exemplified as intravenous and intramuscular administrations. Not only a standard intravenous injection but also intravenous drip infusion can be applied to intravenous administration.

35 For example, it can be prepared as a powder preparation for injection. In this case, one or more than two kinds of water soluble excipients such as mannitol, sugar, lactose, maltose, glucose and fructose may be added to the agent and

dissolved in water. And after putting the mixture into vials or ampoules, they are freeze-dried and then sealed to be an injection preparation.

Although the adult clinical administration dosage for a 5 day may vary from and also depend on administrating methods, ages, weigh, conditions of patients and so on, it is usually 0.01 - 5 mg of the protein.

This invention is described in detail by examples written below. However, this invention is not restricted to 10 these examples.

#### EXAMPLES

**Example 1** Preparation of mature human MP52 of which methionine residue is oxidized

(1) Oxidization of methionine residue of mature human MP52 by 15 hydrogen peroxide (conversion to methionine sulfoxide)

Hydrogen peroxide was added to mature human MP52 (2 mg/ml concentration) dissolved in 2 mM EDTA - 10 mM hydrochloric acid at the final concentration of 0.014% and the solution was reacted at room temperature for more than 20 15 hours.

(2) Separation of methionine oxidized mature human MP52

Mature human MP52 having the amino acid sequence shown in SEQ ID N° 1 (hereafter, unmodified mature human MP52) and methionine oxidized mature human MP52 having the amino acid 25 sequence of SEQ ID N° 5 were separated by using reverse phase HPLC on the basis of a difference between retention times of both proteins. Oxidization increased a hydrophilic property of the proteins and retention time methionine oxidized mature human MP52 on the reverse phase HPLC becomes faster than that 30 of unmodified mature human MP52. The conditions of separation are as follows. For column, Nucleosil 5-C18-300 column (4.6 mm I.D. X 150 mm, GL Science Corp.) was used at the flow rate of 1.3 ml per minute at 45°C; absorbance at 214 nm and 280 nm were measured to detect peaks. For solvent, 35 water containing 0.05% TFA as solution A and acetonitrile containing 0.05% TFA as solution B were used. Elution of proteins were performed with a linear gradient of solution B from 25% to 45% for 80 minutes using an HPLC pump, HP1050

(Hewlett Packard).

Under this condition, unmodified mature human MP52 is eluted at around 51 minutes, whereas methionine oxidized mature human MP52 was eluted at around 47 minutes. Thus, both were easily separated.

(3) Determination of the oxidization of methionine residue

The oxidization of methionine residue was detected by comparing elution patterns of the reverse phase column chromatography of trypsin digested fragments of unmodified mature human MP52 and methionine oxidized mature human MP52.

Unmodified mature human MP52 has seven cysteine residues as shown in SEQ ID N° 1 of the Sequence Listing. Six out of seven cysteine residues form three intramolecular disulfide bonds and the remaining one cysteine forms a dimer. For complete enzymatic digestion, reducing disulfide bond and blocking SH group are required to inhibit rebinding. For this purpose, dithiothreitol was used to reduce the disulfide bond and the cysteine residue was alkylated (S-carboxymethylation) before trypsin digestion.

First, lyophilized unmodified mature human MP52 and methionine oxidized mature human MP52 were dissolved in 8 M urea - 0.2 M ammonium bicarbonate - 2 mM EDTA (pH 8.5) at the final concentration of 1 mg/ml, and 50-fold molar excess of dithiothreitol (DTT) to the cysteine residue was added and reacted at 50°C for 30 minutes. To this solution, 250-fold molar excess of monoiodoacetamide to the cysteine residue was added and reacted for 30 minutes with shading to yield S-carboxymethylated unmodified mature human MP52 and S-carboxymethylated methionine oxidized mature human MP52. Digestion of these proteins was performed by adding trypsin. After four-fold dilution of this solution with water to make the final urea concentration of 2 M, at the weight ratio of 1/50 to the proteins at 37°C for 18 hours, the trypsin digestion was applied to the reverse phase HPLC column to separate all fragments. The conditions of separation are as follows. Nucleosil 5-C18-300 column (4.6 mm I.D. X 150 mm, GL Science Corp.) was used for separation at the flow rate of 1.3 ml per minute at 45°C; absorbance at 214 nm was measured

to detect peaks. For solvent, water containing 0.05% TFA as solution A and acetonitrile containing 0.05% TFA as solution B were used. Elution of peptides was performed by a linear gradient of solution B from 0% to 45% for 90 minutes after  
5 keeping 0% for initial five minutes, using HPLC pump, HP1050 (Hewlett Packard).

Subsequently, amino acid composition analysis was carried out to determine the positions of the digested peptide on the primary structure of reduced alkylated  
10 unmodified mature human MP52 and reduced alkylated methionine oxidized mature human MP52. The operation of the amino acid composition analysis was mainly based on Zoku Seikagaku Zikken Kouza (Tokyo Kagaku Doujin), Vol. 2, Protein Chemistry (I), Section 4. Brief description is given below.

15 Hydrolysis was performed in a vapor of 6 N HCl containing 0.1% phenol at 110°C for 21 hours by using PICO. TAG. WORK STATION (Waters). Following this step, the amino acid composition analysis was carried out by PTC method by using Amino acid standard H (Pierce) as a standard amino acid.

20 PTC-amino acids were separated by reverse phase HPLC using HPLC pump (model 510; Waters), a Wakopak WS-PTC (4.0 mm I.D. X 200 mm; Wako Pure Chemicals), and solvents of PTC amino acids eluent A and PTC amino acids eluent B (both Wako Pure Chemicals).

25 The HPLC retention times of the identified trypsin peptides on the primary structures of unmodified and oxidized mature MP52 were compared each other. The trypsin fragments of mature human MP52 containing methionine residues were three kinds corresponding to: position from 29th to 56th (29-  
30 56; containing 30th methionine) shown in SEQ ID N° 1, position from 57th to 88th (57-88; containing 71st, and 74th methionines) in SEQ ID N° 1, and position from 107th to 119th (107-119; including 111th methionine) in SEQ ID N° 1. The elution time of respective fragments derived from the reduced  
35 alkylated unmodified mature human MP52 were around 84 min, 62 min, and 36 min in order. In comparison, the fragments derived from the reduced alkylated methionine oxidized mature human MP52 (SEQ ID N° 5) were around 80 min, 48 min, and 31

min in order showing the earlier elution than that of the fragments derived from the reduced alkylated unmodified mature human MP52.

On the other hand, there was no difference for other fragments which do not contain methionine. As a result, the specific reaction of oxidization to the methionine residues was determined.

**Example 2** Preparation of mature human MP52 of which methionine residue was S-carboxymethylated

(1) Alkylation of methionine residue of mature human MP52 by moniodoacetic acid

Though the highest reactivity of alkylation using moniodoacetic acid is observed in SH residues of cysteine residue, the alkylation reaction almost selectively occurs in methionine residue in an acidic condition, because all the cysteine residues of unmodified mature human MP52 form disulfide bonds as described before. Therefore, the operation was conducted as follows. Moniodoacetic acid (molar ratio; 50-100 times higher than moles of methionine residue) was added to unmodified mature human MP52 with a concentration of 2 mg/ml dissolved in 10 mM hydrochloric acid and incubated at room temperature for 3-18 hours.

(2) Separation of mature human MP52 of which methionine residue was alkylated

Unmodified mature human MP52 and methionine alkylated mature human MP52 having the amino acid sequence of SEQ ID N° 6 were separated on the basis of a difference in retention times between both proteins by using reverse phase HPLC. The conditions of separation (a column employed, a flow rate, wavelengths for detection, and a pump for HPLC) were the same as those of Example 1 (2). For solvent, water containing 0.05% TFA as solution A and acetonitrile containing 0.05% TFA as solution B were used. Elution of the proteins were performed by a linear gradient of solution B from 30% to 45% for 60 minutes after five minutes of an initial condition.

Under this condition, unmodified mature human MP52 is eluted as one peak around 38 minutes and, in contrast to this, alkylated mature human MP52 showed four peaks (elution



times: 36 min, 34 min, 32 min, and 29 min) other than one peak around 38 minutes which is the elution time of unmodified mature human MP52. Elution time becomes earlier in accordance with proceeding of the reaction, namely, depending on the increasing number of alkylated methionines. These peaks were collected to identify these proteins by the amino acid composition analysis similar to Example 1 (3). In the amino acid composition analysis, alkylated methionines are detected as a separate peak from unmodified methionines, because alkylated methionines are not decomposed by hydrolysis. Namely, the progress of the reaction can be determined by a decrease in methionine peaks.

By the separation experiment, it was known that the elution peak at 29-min was that of all four methionines alkylated mature MP52, the elution peak at 32-min was that of three methionines alkylated one, the elution peak at 34-min was that of two methionines alkylated one, the elution peak at 36-min was one methionine alkylated one. In addition, the elution peak at around 38-min was known as unalkylated one. Amino acid compositions of these peaks were good agreement with those of theoretical values of mature human MP52 except for the value of methionine. Consequently, it is confirmed that the alkylation reaction to methionine residue occurs specifically and the separated peaks show progressing stages of the alkylation reaction differently.

### (3) Determination of the alkylated methionine residues

The alkylated methionine residue was determined by comparing elution patterns of trypsin digested fragments of unmodified mature human MP52 and methionine alkylated mature human MP52 on the reverse phase HPLC.

Similar to Example 1 (3), cysteine residues were blocked by alkylation before trypsin digestion after reduction of disulfide bonds by using dithiothreitol. Since S-carboxymethylation was performed using monoiodoacetic acid for the alkylation of methionine; alkylation of cysteine was performed by using 4-vinyl pyridine as an alkylation reagent for monoiodoacetic acid, which was not similar to Example 1. Alkylation reaction takes place almost selectively in reduced

cysteine at pH 8.5, and hardly in methionine. Thus, the reason of employing different alkylation is to detect side reaction in methionine.

First, lyophilized unmodified mature human MP52 and methionine alkylated mature human MP52 were dissolved in a solution of 6 M guanidine - HCl - 0.4 M Tris-HCl buffer (pH 8.5) at the final concentration of 1 mg/ml, and reduced with 50-fold excess molar of dithiothreitol (DTT) to the cysteine residues at 50°C for 30 minutes. S-pyridyl-ethylation was performed by adding 250-fold excess molar of 4-vinyl pyridine to the cysteine residues and incubated for 30 minutes with shading. The solution was applied on a desalting column (PD-10; Pharmacia) equilibrated with a 6 M guanidine - HCl - 0.4 M Tris-HCl buffer (pH 8.5) to remove excessive reagent and followed by reverse phase HPLC using a reverse phase column (Cosmasil 10C18-300, 4.6 mm I.D. X 100 mm, Nakalai Tesque Inc.). A fraction having both absorption at 280 nm derived from tryptophane and 254 nm derived from pyridine by UV detector was collected.

Following this step, the trypsin digestion was performed by the same method as that of Example 1 (3) to separate digested fragments.

Finally, the position of respective fragments in the primary structure of mature MP52 was determined by the amino acid composition analysis as same as that of Example 1 (3).

Using the reverse phase HPLC, a comparison of elution times of respective trypsin fragments of unmodified mature human MP52 and methionine alkylated mature human MP52 of which position in the primary sequences was determined by the amino acid composition analysis was performed. Trypsin fragments of mature human MP52 containing a methionine residue were three kinds corresponding to: the amino acid position from 29th to 56th (29-56; containing 30th methionine) shown in SEQ ID N° 1, the amino acid position from 57th to 88th (57-88; containing 71st and 74th methionines) in SEQ ID N° 1, and the amino acid position from 107th to 119th (107-119; containing 111th methionine) in SEQ ID N° 1. The elution time of respective fragments derived

from unmodified mature human MP52 were around 77 min, 58 min, and 36 min in order. In comparison, fragments derived from methionine alkylated mature human MP52 (SEQ ID N° 6) were around 74 min, 42 min, and 30 min in order, showing the earlier elution than that of the fragments of unmodified mature human MP52.

On the other hand, the elution time of other fragments without containing methionine was the same between unmodified and methionine alkylated mature human MP52.

In the amino acid composition analysis, only the number of methionine residues derived from the methionine alkylated mature human MP52 was different from the theoretical values. The N-terminal sequence of these fragments were analyzed by using a sequencer (model 476A; Applied Biosystems) and it is confirmed that the alkylation occurred to methionine residues specifically.

**Example 3** Preparation of mature human MP52 of which tryptophane was allylsulphenylated

(1) Allylsulphenylation of tryptophane residues of mature human MP52 by p-nitrophenylchloride

Twenty-fold molar ratio of p-nitrophenylchloride, which dissolved in 100% acetic acid, was added to the unmodified mature human MP52 (2 mg/ml dissolved in 50% acetic acid) and incubated at room temperature for 1 hour.

(2) Separation of allylsulphenylated mature human MP52

Unmodified mature human MP52 and allylsulphenylated mature human MP52 having the amino acid sequence of SEQ ID N° 7 were separated on the basis of a difference in the retention time of column on the reverse phase HPLC. The elution time of allylsulphenylated mature human MP52 delays in comparison with unmodified mature human MP52 on the reverse phase HPLC, which is due to increase in hydrophobic property by allyl sulphenylation. The conditions of separation are as follows; a column employed, a flow rate, and a pump for HPLC were the same as those of Example 1 (2), and column temperature and wavelengths for detection were 40°C, and 214 nm and 365 nm, respectively. For solvent, water containing 0.05% TFA as solution A and acetonitrile

containing 0.05% TFA as solution B were used for elution. The elutions of proteins were performed by a linear gradient of solution B from 25% to 60% for 35 minutes after maintaining for five minutes with 25% of solution B. Under the conditions, unmodified mature human MP52 was eluted around 22 min, and in comparison, tryptophane allylsulphenylated mature human MP52 was eluted around 26 min. The difference of elution times between these proteins allows easy separation of them.

10 (3) Determination of allylsulphenylation of tryptophane

After reduction of disulfide bond by the same method described in Example 1, unmodified mature human MP52 of which cysteine residues were alkylated (S-carboxymethylated) and tryptophane allylsulphenylated mature human MP52 were digested by trypsin, and fragments of the digest were separated by C18 reverse phase column. Amino acid positions of the fragments were determined by the amino acid composition analysis.

The trypsin fragment of mature human MP52 containing tryptophane residues was that corresponding to the position from 29th to 56th positions (29-56; containing 32nd and 35th positions of tryptophane) alone shown in SEQ ID N° 1. Only the elution time (around 95 min) of a fragment containing tryptophane residue, which is derived from allylsulphenylated mature human MP52 (SEQ ID N° 7) delayed in comparison with the elution time (around 84 min) of a fragment derived from the unmodified mature human MP52. On the other hand, the elution time of other fragments without containing tryptophane showed no change. N-terminal sequence analysis showed difference only in tryptophane residue between unmodified and modified mature human MP52.

**Example 4** Test of inhibition of bone morphogenetic activity

BMP-2 antagonistic activity of mature protein of this invention was tested by adding the protein to culture media of MC3T3-E1 cells which are a murine calvarial clonal cell line established by Dr. Kodama et al. and have osteoblast-like properties, or C3H10T  $\frac{1}{2}$  cells which are a mesenchymal and multipotent cell line to differentiate to osteoblast,

chondrocyte, myocyte, fat cell, according to a culture condition. These cell lines were cultured according to the method described by Dr. Takuwa et al. For the MC3T3-E1 cells,  $5 \times 10^3$  cells per  $\text{cm}^2$  were inoculated and cultured in 5  $\alpha$ -MEM medium containing 10% fetal bovine serum for three days. After washing cells with the  $\alpha$ -MEM medium, the medium was replaced into  $\alpha$ -MEM medium containing 0.3% bovine serum albumin. To this medium, the mature protein of the invention with various concentrations and mature rh-BMP-2 (recombinant 10 human BMP-2) were added and then cultured for three days (post-culture). ALPase activity in the cells was measured by colorimetric analysis using p-nitrophenylphosphate as a substrate.

The culture conditions of C3H10T  $\frac{1}{2}$  cells were the same 15 as MC3T3-E1 cells except that the medium used for the pre-culture was BME culture medium containing 10% fetal bovine serum and the medium used for the post-culture was BME culture medium containing 2% fetal bovine serum.

Fig. 1 shows the result of ALPase activity by methionine 20 alkylated mature human MP52 in comparison with that by unmodified mature human MP52 in MC3T3-E1 cells. Both proteins were obtained from the difference in the retention time on the reverse phase HPLC in Example 2. In the figure, the solid line with solid circles represents unmodified 25 mature human MP52, the solid line with solid squares represents one-methionine alkylated mature human MP52, the broken line with solid triangles represents two-methionine alkylated mature human MP52, the solid line with open circles represents three-methionine alkylated mature human MP52, the 30 dotted line with open triangles represents four-methionine alkylated mature human MP52, respectively. The solid circles shown in of the Y-axis present activity of cells without treated by any reagent. As shown in Fig. 1, ALPase inducing activity in MC3T3-E1 cells decreased depending on the 35 progress of alkylation of methionine.

Fig. 2 shows the antagonistic activity of methionine oxidized mature human MP52 obtained in example 1 and tryptophane allylsulphenylated mature human MP52 obtained in

example 3 in two different cell lines. Fig. 2 (A) represents an antagonistic activity against mature rh-BMP-2 in C3H10T  $\frac{1}{2}$  cells. Fig. 2 (B) shows an antagonistic activity against mature human MP52 in MC3T3-E1 cells. In both figures, the solid line with solid circles represents tryptophane allylsulphenylated mature human MP52 and the dotted line with open circles represents methionine oxidized mature human MP52, respectively. In Fig. 2(A), the solid square shows ALPase activity induced by 300 ng/ml of mature rh-BMP-2 alone in C3H10T  $\frac{1}{2}$  cell. In Fig. 2 (B), the solid square shows ALPase activity induced by 600 ng/ml of unmodified mature human MP52 alone in MC3T3-E1 cells. Open squares represent the activity in the experiments without any reagent.

As shown in Fig. 2(A), 300 ng/ml of mature rh-BMP-2 promoted ALPase activity in C3H10T  $\frac{1}{2}$  cell about 40 times higher than the control group. The modified mature human MP52 of this invention inhibited the ALPase activity from 1 equivalent- to 20 equivalent-molar in a dose-dependent manner. Moreover, as shown in Fig. 2(B), 600 ng/ml of the unmodified mature human MP52 promoted ALPase activity in MC3T3-E1 cells about 3 times higher than the control group. The amino acid modified mature human MP52 of this invention inhibited the ALPase activity from 1 equivalent- to 10 equivalent-molar in a dose-dependent manner.

## Sequence Listing Free Text

<210> 1

<223> Mature MP52

5

<210> 2

<223> Mature BMP-2

<210> 3

10 <223> Mature BMP-4

<210> 4

<223> Mature BMP-7

15 <210> 5

<223> Mature MP52 protein. Note : 30th, 71st, 74th and  
111th Met are modified to Met sulfoxide.

<210> 6

20 <223> Mature MP52 protein. Note : 30th and/or 71st  
and/or 74th and/or 111th Met are modified to  
s-carboxymethyl Met.

<210> 7

25 <223> Mature MP52 protein. Note : 32nd and 35th Trp are  
modified to allylsulphenyl Trp.

What is claimed is:

1. A mature protein having an antagonistic activity against bone morphogenetic proteins, obtained by converting at least one residue among methionine residues or tryptophane residues existing in the amino acid sequence of mature human MP52 (SEQ ID N° 1) to a hydrophilic residue by chemical modification, or replacing said residues with a hydrophilic amino acid residue or a polar amino acid residue.
2. The mature protein according to claim 1, wherein the chemical modification for said methionine residue is an oxidization reaction.
3. The mature protein according to claim 2 in which four methionine residues are oxidized and having the amino acid sequence of SEQ ID N° 5.
4. The mature protein according to claim 1, wherein the chemical modification for said methionine residue is an alkylation reaction.
5. The mature protein according to claim 4 wherein the alkylation reaction is S-carboxymethylation in which at least one methionine residue is S-carboxymethylated and having the amino acid sequence of SEQ ID N° 6.
6. The mature protein according to claim 1, wherein the chemical modification for said tryptophane residue is an allylsulphenylation reaction.
7. The mature protein according to claim 6 in which two tryptophane residues are allylsulphenylated and having the amino acid sequence of SEQ ID N° 7.
8. The mature protein according to claims 1 to 7, wherein said mature human MP52 is a dimer protein.
9. A mature protein having an antagonistic activity against bone morphogenetic proteins, obtained by converting at least one residue of tryptophane residues existing in the amino acid sequences of mature human BMP-2 (SEQ ID N° 2), mature human BMP-4 (SEQ ID N° 3) or mature human BMP-7 (SEQ ID N° 4) to a hydrophilic residue by chemical modification, or replacing said residues with a hydrophilic amino acid residue or a polar amino acid residue.



10. A mature protein having an antagonistic activity against bone morphogenetic proteins, obtained by replacing at least one amino acid residue of three hydrophobic amino acid residues, among said hydrophobic amino acid residues relating  
5 to a receptor binding site in the amino acid sequences of mature human BMP-2 (SEQ ID N° 2), mature human BMP-4 (SEQ ID N° 3), or mature human BMP-7 (SEQ ID N° 4), which are located in positions corresponding to those of methionine residues located in 30th, 71st, and 74th positions of the amino acid  
10 sequence of mature human MP52 (SEQ ID N° 1) with a hydrophilic amino acid residue or a polar amino acid residue.
11. The mature protein according to claim 9 or 10, wherein said mature human BMP-2, mature human BMP-4, or mature human BMP-7 is a dimer protein.
- 15 12. An agent for therapy and/or prevention of ectopic ossification, containing a mature protein according to any one of claims 1 to 11 as an effective ingredient showing an antagonistic activity against a bone morphogenetic protein.
13. An agent for therapy and/or prevention of metabolic  
20 diseases with calcification, containing a mature protein according to any one of claims 1 to 11 as an effective ingredient showing an antagonistic activity against a bone morphogenetic protein.

1/2




FIGURE 1

2/2




FIGURE 2B




FIGURE 2A

## SEQUENCE LISTING

<110> Hoechst Marion Roussel

<120> MATURE PROTEIN HAVING ANTAGONIST ACTIVITY AGAINST BONE  
MORPHOGENETIC PROTEIN.

<130> JH98K011 PCT SEQUENCES IN ENGLISH

<140>

<141>

<150> 10-288103

<151> 1998-10-09

<160> 7

<170> PatentIn Ver. 2.1

<210> 1

<211> 119

<212> PRT

<213> Human

<220>

<221> CHAIN

<222> (1) .. (119)

<223> Mature MP52

<300>

<301> MAKISHIMA, Fusoa

TAKAMATSU, Hiroyuki

MIKI, Hideo

KAWAI, Shinji

KIMURA, Michio

MATSUMOTO, Tomoaki

KATSUURA, Mieko

ENOMOTO, Koichi

2

SATO, Yusuke

&lt;302&gt; Novel protein and process for producing the same.

&lt;310&gt; WO 96/33215

&lt;312&gt; 1996-10-24

&lt;313&gt; 1 TO 119

&lt;400&gt; 1

Pro Ser Ala Thr Arg Gln Gly Lys Arg Pro Ser Lys Asn Leu Lys Ala

1 5 10 15

Arg Cys Ser Arg Lys Ala Leu His Val Asn Phe Lys Asp Met Gly Trp

20 25 30

Asp Asp Trp Ile Ile Ala Pro Leu Glu Tyr Glu Ala Phe His Cys Glu

35 40 45

Gly Leu Cys Glu Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His

50 55 60

Ala Val Ile Gln Thr Leu Met Asn Ser Met Asp Pro Glu Ser Thr Pro

65 70 75 80

Pro Thr Cys Cys Val Pro Thr Arg Leu Ser Pro Ile Ser Ile Leu Phe

85 90 95

Ile Asp Ser Ala Asn Asn Val Val Tyr Lys Gln Tyr Glu Asp Met Val

100 105 110

Val Glu Ser Cys Gly Cys Arg

115

&lt;210&gt; 2

&lt;211&gt; 114

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;220&gt;

&lt;221&gt; CHAIN

&lt;222&gt; (1) .. (114)

&lt;223&gt; Mature BMP-2

&lt;300&gt;

&lt;301&gt; WANG, Elizabeth A.

WOZNEY, John M.

ROSEN, Vicki A.

&lt;302&gt; Novel osteoinductive compositions.

&lt;310&gt; WO 88/00205

&lt;312&gt; 1988-01-14

&lt;313&gt; 1 TO 114

&lt;400&gt; 2

Gln Ala Lys His Lys Gln Arg Lys Arg Leu Lys Ser Ser Cys Lys Arg

1

5

10

15

His Pro Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp Trp Ile

20

25

30

Val Ala Pro Pro Gly Tyr His Ala Phe Tyr Cys His Gly Glu Cys Pro

35

40

45

Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala Ile Val Gln

50

55

60

Thr Leu Val Asn Ser Val Asn Ser Lys Ile Pro Lys Ala Cys Cys Val

65

70

75

80

Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp Glu Asn Glu

85

90

95

Lys Val Val Leu Lys Asn Tyr Gln Asp Met Val Val Glu Gly Cys Gly

100

105

110

Cys Arg

<210> 3

<211> 116

<212> PRT

<213> Human

<220>

<221> CHAIN

<222> (1) .. (116)

<223> Mature BMP-4

<300>

<301> WOZNEY, John M.

ROSEN, Vicki

CELESTE, Anthony J.

MITSOCK, Lisa M.

WHITTERS, Matthew J.

KRIZ, Ronald W.

HEWICK, Rodney M.

WANG, Elizabeth A.

<302> Novel regulators of bone formation : molecular clones  
and activities.

<303> Science

<304> 242

<305> 4885

<306> 1528-1534

<307> 1988-12-16

<308> Genbank/M22490

<313> 1 TO 116

<400> 3

Ser Pro Lys His His Ser Gln Arg Ala Arg Lys Lys Asn Lys Asn Cys

1

5

10

15

Arg Arg His Ser Leu Tyr Val Asp Phe Ser Asp Val Gly Trp Asn Asp

20

25

30

Trp Ile Val Ala Pro Pro Gly Tyr Gln Ala Phe Tyr Cys His Gly Asp

35

40

45

Cys Pro Phe Pro Leu Ala Asp His Leu Asn Ser Thr Asn His Ala Ile  
50 55 60

Val Gln Thr Leu Val Asn Ser Val Asn Ser Ser Ile Pro Lys Ala Cys  
65 70 75 80

Cys Val Pro Thr Glu Leu Ser Ala Ile Ser Met Leu Tyr Leu Asp Glu  
85 90 95

Tyr Asp Lys Val Val Leu Lys Asn Tyr Gln Glu Met Val Val Glu Gly  
100 105 110

Cys Gly Cys Arg  
115

<210> 4

<211> 139

<212> PRT

<213> Human

<220>

<221> CHAIN

<222> (1) .. (139)

<223> Mature BMP-7

<300>

<301> OZKAYNAK, Engin

RUEGER, David C.

DRIER, Eric A.

CORBETT, Clare

RIDGE, Richard J.

SAMPATH, Kuber T.

OPPERMANN, Hermann

<302> OP-1 cDNA encodes an osteogenic protein in the TGF-beta family.



<303> EMBO J.

<304> 9

<305> 7

<306> 2085-2093

<307> 1990

<308> EMBL data library/X51801

<313> 1 TO 139

<400> 4

Ser Thr Gly Ser Lys Gln Arg Ser Gln Asn Arg Ser Lys Thr Pro Lys  
1 5 10 15

Asn Gln Glu Ala Leu Arg Met Ala Asn Val Ala Glu Asn Ser Ser Ser  
20 25 30

Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe Arg  
35 40 45

Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala Ala  
50 55 60

Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met Asn  
65 70 75 80

Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe Ile Asn Pro  
85 90 95

Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala Ile  
100 105 110

Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu Lys Lys Tyr  
115 120 125

Arg Asn Met Val Val Arg Ala Cys Gly Cys His  
130 135

&lt;210&gt; 5

&lt;211&gt; 119

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;220&gt;

&lt;221&gt; CHAIN

&lt;222&gt; (1)..(119)

<223> Mature MP52 protein. Note : 30th, 71st, 74th and  
111th Met are modified to Met sulfoxide.

&lt;400&gt; 5

Pro Ser Ala Thr Arg Gln Gly Lys Arg Pro Ser Lys Asn Leu Lys Ala

1

5

10

15

Arg Cys Ser Arg Lys Ala Leu His Val Asn Phe Lys Asp Met Gly Trp

20

25

30

Asp Asp Trp Ile Ile Ala Pro Leu Glu Tyr Glu Ala Phe His Cys Glu

35

40

45

Gly Leu Cys Glu Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His

50

55

60

Ala Val Ile Gln Thr Leu Met Asn Ser Met Asp Pro Glu Ser Thr Pro

65

70

75

80

Pro Thr Cys Cys Val Pro Thr Arg Leu Ser Pro Ile Ser Ile Leu Phe

85

90

95

Ile Asp Ser Ala Asn Asn Val Val Tyr Lys Gln Tyr Glu Asp Met Val

100

105

110

Val Glu Ser Cys Gly Cys Arg

115

&lt;210&gt; 6

&lt;211&gt; 119

&lt;212&gt; PRT

&lt;213&gt; Human

&lt;220&gt;

&lt;221&gt; CHAIN

&lt;222&gt; (1)..(119)

<223> Mature MP52 protein. Note : 30th and/or 71st  
and/or 74th and/or 111th Met are modified to  
s-carboxymethyl Met.

&lt;400&gt; 6

Pro Ser Ala Thr Arg Gln Gly Lys Arg Pro Ser Lys Asn Leu Lys Ala  
1 5 10 15

Arg Cys Ser Arg Lys Ala Leu His Val Asn Phe Lys Asp Met Gly Trp  
20 25 30

Asp Asp Trp Ile Ile Ala Pro Leu Glu Tyr Glu Ala Phe His Cys Glu  
35 40 45

Gly Leu Cys Glu Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His  
50 55 60

Ala Val Ile Gln Thr Leu Met Asn Ser Met Asp Pro Glu Ser Thr Pro  
65 70 75 80

Pro Thr Cys Cys Val Pro Thr Arg Leu Ser Pro Ile Ser Ile Leu Phe  
85 90 95

Ile Asp Ser Ala Asn Asn Val Val Tyr Lys Gln Tyr Glu Asp Met Val  
100 105 110

Val Glu Ser Cys Gly Cys Arg  
115

<210> 7

<211> 119

<212> PRT

<213> Human

<220>

<221> CHAIN

<222> (1)..(119)

<223> Mature MP52 protein. Note : 32nd and 35th Trp are  
modified to allylsulphenyl Trp.

<400> 7

Pro Ser Ala Thr Arg Gln Gly Lys Arg Pro Ser Lys Asn Leu Lys Ala  
1 5 10 15

Arg Cys Ser Arg Lys Ala Leu His Val Asn Phe Lys Asp Met Gly Trp  
20 25 30

Asp Asp Trp Ile Ile Ala Pro Leu Glu Tyr Glu Ala Phe His Cys Glu  
35 40 45

Gly Leu Cys Glu Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His  
50 55 60

Ala Val Ile Gln Thr Leu Met Asn Ser Met Asp Pro Glu Ser Thr Pro  
65 70 75 80

Pro Thr Cys Cys Val Pro Thr Arg Leu Ser Pro Ile Ser Ile Leu Phe  
85 90 95

Ile Asp Ser Ala Asn Asn Val Val Tyr Lys Gln Tyr Glu Asp Met Val  
100 105 110

Val Glu Ser Cys Gly Cys Arg  
115

# INTERNATIONAL SEARCH REPORT

Int. Patent Application No  
PCT/IB 99/01621

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07K14/51 A61K38/18 A61P19/00 A61P21/00 A61P9/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 691 349 A (HOECHST JAPAN) 10 January 1996 (1996-01-10) cited in the application the whole document -----	1-13



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 January 2000

Date of mailing of the international search report

02/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Groenendijk, M

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 99/01621

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0691349 A	10-01-1996	AU 695241 B	13-08-1998
		AU 2337595 A	18-01-1996
		CA 2153109 A	05-01-1996
		FI 953269 A	05-01-1996
		HU 72068 A	28-03-1996
		JP 8176191 A	09-07-1996
		NO 952635 A	05-01-1996
		US 5908828 A	01-06-1999
-----			